MCID: BSL007
MIFTS: 65

Basal Cell Carcinoma malady

Categories: Genetic diseases, Cancer diseases, Skin diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Basal Cell Carcinoma

About this section

Aliases & Descriptions for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 11 13 68
Basal Cell Neoplasm 11 27 68
Basal Cell Cancer 11 50 68
Malignant Basal Cell Tumor 11 68
Experimental Organism Basal Cell Carcinoma 68
Nodulo-Ulcerative Basal Cell Carcinoma 68
Malignant Basal Cell Neoplasm 11
Basal Cell Carcinoma of Skin 11
 
Basal Cell Carcinoma Nos 11
Basal Cell Neoplasm Nos 11
Epithelioma Basal Cell 11
Carcinoma, Basal Cell 39
Neoplasms, Basal Cell 39
Carcinoma Basal Cell 50
Basal Cell Tumor 11
Rodent Ulcer 11

Classifications:



Summaries for Basal Cell Carcinoma

About this section
Wikipedia:71 Basal cell carcinoma (BCC) is the most common skin cancer, and one of the most common cancers in the... more...

MalaCards based summary: Basal Cell Carcinoma, also known as basal cell neoplasm, is related to basal cell carcinoma 1 and superficial basal cell carcinoma. An important gene associated with Basal Cell Carcinoma is PTCH1 (Patched 1), and among its related pathways are Glypican 3 network and Tgif disruption of Shh signaling. The drug fluorouracil has been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and t cells, and related mouse phenotypes are hearing/vestibular/ear and pigmentation.

Disease Ontology:11 A skin carcinoma affecting basal cells.

Related Diseases for Basal Cell Carcinoma

About this section

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 6
Basal Cell Carcinoma 5 Basal Cell Carcinoma 4
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm basal cell carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 292)
idRelated DiseaseScoreTop Affiliating Genes
1basal cell carcinoma 134.1PTCH1, PTCH2, SMO
2superficial basal cell carcinoma33.9KRT17, KRT7
3infiltrative basal cell carcinoma33.5KRT15, KRT17, KRT19, KRT20
4sarcomatoid basal cell carcinoma33.4KRT15, KRT17, KRT20, KRT7, TP53
5anal margin basal cell carcinoma33.4KRT17, KRT20, PTCH1, SUFU
6basal cell carcinoma 733.0CTNNB1, GLI1, KRT19, SHH, SMO, TP53
7basal cell nevus syndrome32.9CTNNB1, GLI1, GLI2, PTCH1, PTCH2, SHH
8nodular basal cell carcinoma12.2
9infundibulocystic basal cell carcinoma12.2
10morpheaform basal cell carcinoma12.2
11pigmented basal cell carcinoma12.1
12adenoid basal cell carcinoma12.1
13clear cell basal cell carcinoma12.1
14cystic basal cell carcinoma12.1
15metatypical basal cell carcinoma12.1
16micronodular basal cell carcinoma12.1
17fibroepithelial basal cell carcinoma12.1
18basal cell carcinoma, multiple12.0
19external ear basal cell carcinoma12.0
20vulva basal cell carcinoma12.0
21scrotum basal cell carcinoma12.0
22follicular basal cell carcinoma12.0
23signet ring basal cell carcinoma12.0
24basal cell carcinoma 211.9
25basal cell carcinoma 311.9
26basal cell carcinoma 611.9
27basal cell carcinoma 511.9
28basal cell carcinoma 411.9
29penis basal cell carcinoma11.9
30sebaceous basal cell carcinoma11.9
31bazex syndrome11.8
32rombo syndrome11.8
33brooke-spiegler syndrome11.2
34multiple familial trichoepithelioma11.2
35adamantinoid basal cell epithelioma11.0
36trichoepithelioma, multiple familial, 111.0
37eosinophilic granuloma10.9
38prostate cancer 110.8
39prostate cancer10.8
40prostate cancer, hereditary, 1210.8
41xeroderma pigmentosum, variant type10.8
42prostate cancer, hereditary, 1310.8
43cerebrooculofacioskeletal syndrome 310.8
44prostate cancer, hereditary, 210.8
45prostate cancer, hereditary, 1110.8
46clear cell acanthoma10.8
47inflammatory linear verrucous epidermal nevus10.8
48squamous cell carcinoma10.5
49keratosis10.4
50melanoma10.4

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to basal cell carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.8CTNNB1, GLI2, GLI3, MC1R, SHH, SMO
2MP:00011869.8CTNNB1, GLI3, KRT17, MC1R, PTCH1, SUFU
3MP:00053679.6CTNNB1, GLI1, GLI3, KRT7, PTCH1, SHH
4MP:00053899.3CTNNB1, GLI1, GLI2, GLI3, KRT19, PTCH1
5MP:00053719.3CTNNB1, GLI1, GLI2, GLI3, MC1R, PTCH1
6MP:00053799.2CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT19
7MP:00053889.2CTNNB1, GLI1, GLI2, GLI3, HHIP, PTCH1
8MP:00053859.0CTNNB1, GLI3, KRT19, MMP11, PTCH1, PTCH2
9MP:00020069.0CTNNB1, GLI1, KRT19, MC1R, MMP11, PTCH1
10MP:00028738.9CTNNB1, GLI1, GLI2, GLI3, KRT19, PTCH1
11MP:00053908.9CTNNB1, GLI2, GLI3, KRT19, PTCH1, SHH
12MP:00053808.8CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT19
13MP:00107718.8CTNNB1, GLI2, GLI3, KRT17, KRT19, MC1R
14MP:00030128.8CTNNB1, GLI1, GLI2, GLI3, KRT17, KRT19
15MP:00053828.8CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT17
16MP:00036318.6CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT19
17MP:00053918.6CTNNB1, GLI2, GLI3, HHIP, PTCH1, SHH
18MP:00053818.4CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT17
19MP:00053788.3CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT17
20MP:00053848.1CTNNB1, GLI1, GLI2, GLI3, HHIP, KRT17

Drugs & Therapeutics for Basal Cell Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erivedge16 44 VISMODEGIB Genentech January 2012
FDA Label: Erivedge
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:16 ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:14 1. Smoothened homolog
Mechanism of Action:16 
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
2
Intron A16 44 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Odomzo16 44 SONIDEGIB PHOSPHATE Novartis Jul-15
FDA Label: Odomzo
Disease/s that Drug Treats:locally advanced basal cell carcinoma
Indications and Usage:16 ODOMZO is a hedgehog pathway inhibitor indicated for the treatment ofadult patients with locally advanced basal cell carcinoma (BCC) that hasrecurred following surgery or radiation therapy, or those who are notcandidates for surgery or radiation therapy. (1)
DrugBank Targets: -
Mechanism of Action:16 
Target: Smoothened
Action: inhibitor
FDA: Sonidegib is an inhibitor of the Hedgehog pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane proteininvolved in Hedgehog signal transduction.

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 329)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Aminolevulinic acidapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1165106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
2
Imiquimodapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 114099011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
3
EverolimusapprovedPhase 4, Phase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
4
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 292279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
6
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
7
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
8
Tacrolimusapproved, investigationalPhase 4, Phase 21102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
9
Triamcinoloneapproved, vet_approvedPhase 4, Phase 2510124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
10
Acetylcysteineapproved, investigationalPhase 4330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
11
Nitric OxideapprovedPhase 461710102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
12
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 2128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
13Anti-Bacterial AgentsPhase 4, Phase 1, Phase 211226
14Antibiotics, AntitubercularPhase 4, Phase 1, Phase 27180
15Adjuvants, ImmunologicPhase 4, Phase 3, Phase 2, Phase 12554
16Antirheumatic AgentsPhase 4, Phase 2, Phase 310956
17Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
18Antiviral AgentsPhase 4, Phase 2, Phase 19967
19Photosensitizing AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1492
20Methyl 5-aminolevulinatePhase 4, Phase 3, Phase 2, Phase 160
21Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15806
22interferonsPhase 4, Phase 3, Phase 2, Phase 12175
23AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
24Interferon InducersPhase 4, Phase 3, Phase 2, Phase 1294
25Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
26MicronutrientsPhase 4, Phase 3, Phase 2, Phase 16001
27HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 114415
28VitaminsPhase 4, Phase 3, Phase 2, Phase 15282
29Autonomic AgentsPhase 4, Phase 3, Phase 1, Phase 210150
30Trace ElementsPhase 4, Phase 3, Phase 2, Phase 16001
31AntioxidantsPhase 4, Phase 3, Phase 2, Phase 13050
32vitamin dPhase 4, Phase 21724
33Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
34Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17443
35ErgocalciferolsPhase 4, Phase 21281
36Bone Density Conservation AgentsPhase 4, Phase 2, Phase 13376
37Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
38Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13696
39Triamcinolone hexacetonidePhase 4, Phase 2510
40Triamcinolone diacetatePhase 4, Phase 2510
41triamcinolone acetonidePhase 4, Phase 2510
42Neurotransmitter AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 118340
43Calcineurin InhibitorsPhase 4, Phase 21622
44Tin FluoridesPhase 4264
45
Proton pump inhibitorsPhase 41123
Synonyms:
 
PPIs
46Interferon-alphaPhase 41152
47CalcifediolPhase 45019356-17-3
48Respiratory System AgentsPhase 44997
49Anti-Asthmatic AgentsPhase 43488
50Bronchodilator AgentsPhase 42965

Interventional clinical trials:

(show top 50)    (show all 342)
idNameStatusNCT IDPhase
1Imiquimod 5% Cream for the Treatment of Periocular Basal Cell CarcinomaUnknown statusNCT00803907Phase 4
2Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage MethylaminolevulinateUnknown statusNCT01491711Phase 4
3A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaApproved for marketingNCT01160250Phase 4
4Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After CurettageCompletedNCT00314756Phase 4
5Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell CarcinomaCompletedNCT00204555Phase 4
6Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)CompletedNCT00581425Phase 4
7CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention TrialCompletedNCT00847912Phase 4
8Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsCompletedNCT00129961Phase 4
9The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory BiomarkerCompletedNCT02666976Phase 4
10Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.CompletedNCT01939977Phase 4
11VISmodegib for ORbital and Periocular Basal Cell CarcinomaRecruitingNCT02436408Phase 4
12N-Acetylcysteine and Arginine Administration in Diabetic PatientsTerminatedNCT00569465Phase 4
13Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological ControlUnknown statusNCT00663650Phase 3
14TREatment of degeNerative and Neoplastic Diseases With RituximabUnknown statusNCT01277172Phase 2, Phase 3
15Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% CreamCompletedNCT00189306Phase 3
16Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and CryosurgeryCompletedNCT01212562Phase 3
17A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell CarcinomaCompletedNCT00189241Phase 3
18Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell CarcinomaCompletedNCT00472108Phase 3
19Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell CarcinomaCompletedNCT00469417Phase 3
20A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma RecurrenceCompletedNCT00129519Phase 3
21Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell CarcinomaCompletedNCT01212549Phase 3
22Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin CancerCompletedNCT00066872Phase 3
23Metvix PDT in Patients With "High Risk" Basal Cell CarcinomaCompletedNCT00473343Phase 3
24Topical Green Tea Ointment in Treatment of Superficial Skin CancerCompletedNCT02029352Phase 2, Phase 3
25Aldara for the Treatment of Large and/or Multiple sBCCCompletedNCT00189280Phase 3
26PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call CarcinomaCompletedNCT00472043Phase 3
27Fractional CO2 Laser Assisted Photodynamic TherapyCompletedNCT01260987Phase 2, Phase 3
28Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerCompletedNCT00007631Phase 3
29Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin CancerCompletedNCT00005884Phase 3
30Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.CompletedNCT00272428Phase 3
31PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin CancerCompletedNCT00472459Phase 3
32Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
33Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
34Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
35Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
36Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
37A Study of Dulaglutide (LY2189265) in Participants With Type II DiabetesCompletedNCT02152371Phase 3
38Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell CarcinomaRecruitingNCT02242929Phase 3
39Radiotherapy or Imiquimod in Complex Lentigo MalignaRecruitingNCT02394132Phase 3
40Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyRecruitingNCT02445391Phase 3
41A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerRecruitingNCT03168880Phase 3
4218F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyRecruitingNCT03042416Phase 3
43Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic TherapyActive, not recruitingNCT02144077Phase 3
44Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
45Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Active, not recruitingNCT01362140Phase 3
46Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With TActive, not recruitingNCT01640405Phase 3
47Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.TerminatedNCT00049959Phase 3
48Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted PatientsTerminatedNCT01532453Phase 3
49Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)WithdrawnNCT03070691Phase 2, Phase 3
50Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: neoplasms, basal cell

Genetic Tests for Basal Cell Carcinoma

About this section

Genetic tests related to Basal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Basal Cell Carcinoma27

Anatomical Context for Basal Cell Carcinoma

About this section

MalaCards organs/tissues related to Basal Cell Carcinoma:

36
Skin, Prostate, T cells, Testes, Thyroid, Breast, Liver

Publications for Basal Cell Carcinoma

About this section

Articles related to Basal Cell Carcinoma:

(show top 50)    (show all 1740)
idTitleAuthorsYear
1
Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma. (27718152)
2017
2
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. (28073840)
2017
3
Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma. (28177523)
2017
4
Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. (28089000)
2017
5
Use of a cotton-tipped applicator for superior clinical diagnosis and biopsy of suspected basal cell carcinoma of the nasal ala. (27986150)
2017
6
The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. (28088877)
2017
7
Reflectance confocal microscopy as a noninvasive diagnostic tool for naevoid basal cell carcinoma syndrome management. (28044368)
2017
8
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. (28087032)
2017
9
Dynamic Thiol/Disulphide Homeostasis in patients with Basal Cell Carcinoma. (28067074)
2017
10
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. (28373119)
2017
11
Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. (28088999)
2017
12
Nevoid Basal Cell Carcinoma Syndrome - Clinical and Radiological Findings of Three Cases. (27630800)
2016
13
Ameloblastoma vs basal cell carcinoma: an immunohistochemical comparison. (27806852)
2016
14
Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma. (27406386)
2016
15
Treatment of Pigmented Basal Cell Carcinoma with 3a88mm Surgical Margin in Asians. (27652267)
2016
16
Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. (28002101)
2016
17
Nodulocystic Basal Cell Carcinoma Arising Directly from a Seborrheic Keratosis: A Rare Case Report. (27512194)
2016
18
Preoperative prediction of histopathologic outcome in basal cell carcinoma - flat surface and multiple small erosions predict superficial basal cell carcinoma in lighter skin types. (26921200)
2016
19
Pigmented basal cell carcinoma mimicking a superficial spreading melanoma. (28076343)
2016
20
Marking sutures to orientate specimens of basal cell carcinoma: do they really make a difference? (27126978)
2016
21
Case of nodular melanoma on the upper eyelid dermoscopically mimicking pigmented basal cell carcinoma. (27649925)
2016
22
The Rare Phenomenon of Tumor-to-Tumor Metastasis: Melanoma Metastatic to a Basal Cell Carcinoma. (27605090)
2016
23
A retrospective study on the effectiveness of curettage and electrodesiccation for clinically suspected primary nodular basal cell carcinoma. (27229620)
2016
24
Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry. (27902821)
2016
25
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. (27574458)
2016
26
The activity and tissue distribution of thioredoxin reductase in basal cell carcinoma. (27601162)
2016
27
The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. (27636236)
2016
28
Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma - a prospective, consecutive, cohort study of 168 cases. (27146027)
2016
29
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. (27714753)
2016
30
Diagnostic Accuracy in Subtyping Basal Cell Carcinoma by Clinical Diagnosis Compared with Punch Biopsy. (27140830)
2016
31
Soluble interleukin-2 receptor I+ and interleukin-2 serum levels in patients with basal cell carcinoma. (27605896)
2016
32
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. (27359199)
2016
33
Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. (26985197)
2016
34
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015. (27904293)
2016
35
PCR Quantification of D. folliculorum in Periocular Basal Cell Carcinoma. (27615600)
2016
36
Incidence of eyelid basal cell carcinoma in England: 2000-2010. (27130914)
2016
37
A Case-Control Study of Involvement of Oxidative DNA Damage and Alteration of Antioxidant Defense System in Patients with Basal Cell Carcinoma: Modulation by Tumor Removal. (27057281)
2016
38
Pigmented Basal Cell Carcinoma: Increased Melanin or Increased Melanocytes? (27612950)
2016
39
Unusual Presentation of Pigmented Basal Cell Carcinoma of Face: Surgical Challenge. (27630973)
2016
40
Altered Expression of PRKX, WNT3 and WNT16 in Human Nodular Basal Cell Carcinoma. (27630294)
2016
41
Adenoid basal cell carcinoma: a rare facet of basal cell carcinoma. (27095806)
2016
42
Differentiation of Basal Cell Carcinoma Subtypes in Multi-Beam Swept Source Optical Coherence Tomography (MSS-OCT). (27168263)
2016
43
Basal Cell Carcinoma of the Dorsal Foot: An Update and Comprehensive Review of the Literature. (27631459)
2016
44
Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma. (27218790)
2016
45
Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study. (27152747)
2016
46
A Case of Orbital Myiasis in Recurrent Eyelid Basal Cell Carcinoma Invasive into the Orbit. (27595028)
2016
47
Topical Photodynamic Therapy for Primary Bowen's Disease and Basal Cell Carcinoma - Optimising Patient Selection. (28028807)
2016
48
Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? (27256516)
2016
49
Gorlin Syndrome, Vulvar Basal Cell Carcinomas, Vismodegib, and Lichen Sclerosus: From the ISSVD Case Consultation Committee. (27105331)
2016
50
Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. (27519350)
2016

Variations for Basal Cell Carcinoma

About this section

Cosmic variations for Basal Cell Carcinoma:

8 (show top 50)    (show all 223)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM44130TP53skin,NS,carcinoma,basal cell carcinomac.477C>Tp.A159A20
2COSM43920TP53skin,NS,carcinoma,basal cell carcinomac.680C>Tp.S227F20
3COSM10705TP53skin,NS,carcinoma,basal cell carcinomac.586C>Tp.R196*20
4COSM10654TP53skin,NS,carcinoma,basal cell carcinomac.637C>Tp.R213*20
5COSM14464PTCH1skin,NS,carcinoma,basal cell carcinomac.1804C>Tp.R602*20
6COSM45774TP53skin,NS,carcinoma,basal cell carcinomac.899C>Gp.P300R20
7COSM29068PTCH1skin,NS,carcinoma,basal cell carcinomac.1603-1G>Ap.?20
8COSM11084TP53skin,NS,carcinoma,basal cell carcinomac.517G>Ap.V173M20
9COSM10662TP53skin,NS,carcinoma,basal cell carcinomac.743G>Ap.R248Q20
10COSM29055PTCH1skin,NS,carcinoma,basal cell carcinomac.2050G>Tp.E684*20
11COSM14440PTCH1skin,NS,carcinoma,basal cell carcinomac.1093C>Tp.Q365*20
12COSM44097TP53skin,NS,carcinoma,basal cell carcinomac.530C>Tp.P177L20
13COSM44603TP53skin,NS,carcinoma,basal cell carcinomac.835G>Ap.G279R20
14COSM29048PTCH1skin,NS,carcinoma,basal cell carcinomac.1347+1G>Ap.?20
15COSM45424TP53skin,NS,carcinoma,basal cell carcinomac.781A>Tp.S261C20
16COSM26356PTCH1skin,NS,carcinoma,basal cell carcinomac.834G>Ap.W278*20
17COSM44435TP53skin,NS,carcinoma,basal cell carcinomac.96+1G>Ap.?20
18COSM564NRASskin,NS,carcinoma,basal cell carcinomac.35G>Ap.G12D20
19COSM10659TP53skin,NS,carcinoma,basal cell carcinomac.817C>Tp.R273C20
20COSM10728TP53skin,NS,carcinoma,basal cell carcinomac.839G>Ap.R280K20
21COSM17453PTCH1skin,NS,carcinoma,basal cell carcinomac.3196G>Tp.E1066*20
22COSM1651689PTCH1skin,NS,carcinoma,basal cell carcinomac.250C>Tp.Q84*20
23COSM43837TP53skin,NS,carcinoma,basal cell carcinomac.843C>Gp.D281E20
24COSM29071PTCH1skin,NS,carcinoma,basal cell carcinomac.3549+5G>Ap.?20
25COSM10749TP53skin,NS,carcinoma,basal cell carcinomac.830G>Tp.C277F20
26COSM17592PTCH1skin,NS,carcinoma,basal cell carcinomac.3605C>Tp.P1202L20
27COSM26370PTCH1skin,NS,carcinoma,basal cell carcinomac.286A>Tp.K96*20
28COSM26363PTCH1skin,NS,carcinoma,basal cell carcinomac.2446C>Tp.Q816*20
29COSM26378PTCH1skin,NS,carcinoma,basal cell carcinomac.1848-1G>Ap.?20
30COSM144244PTCH1skin,NS,carcinoma,basal cell carcinomac.994A>Tp.R332*20
31COSM483HRASskin,NS,carcinoma,basal cell carcinomac.35G>Tp.G12V20
32COSM17600PTCH1skin,NS,carcinoma,basal cell carcinomac.2207C>Tp.A736V20
33COSM17608PTCH1skin,NS,carcinoma,basal cell carcinomac.1161G>Ap.W387*20
34COSM17547PTCH1skin,NS,carcinoma,basal cell carcinomac.1511C>Ap.P504Q20
35COSM17495PTCH1skin,NS,carcinoma,basal cell carcinomac.1229G>Ap.S410N20
36COSM45322TP53skin,NS,carcinoma,basal cell carcinomac.757A>Gp.T253A20
37COSM17473PTCH1skin,NS,carcinoma,basal cell carcinomac.2308C>Tp.R770*20
38COSM17467PTCH1skin,NS,carcinoma,basal cell carcinomac.1726C>Tp.Q576*20
39COSM10995TP53skin,NS,carcinoma,basal cell carcinomac.580C>Tp.L194F20
40COSM17598PTCH1skin,NS,carcinoma,basal cell carcinomac.550C>Tp.Q184*20
41COSM43582TP53skin,NS,carcinoma,basal cell carcinomac.454C>Tp.P152S20
42COSM10656TP53skin,NS,carcinoma,basal cell carcinomac.742C>Tp.R248W20
43COSM17490PTCH1skin,NS,carcinoma,basal cell carcinomac.3584C>Tp.T1195I20
44COSM216037SMOskin,NS,carcinoma,basal cell carcinomac.1234C>Tp.L412F20
45COSM29052PTCH1skin,NS,carcinoma,basal cell carcinomac.724C>Tp.Q242*20
46COSM10650TP53skin,NS,carcinoma,basal cell carcinomac.529C>Tp.P177S20
47COSM3942015SMOskin,NS,carcinoma,basal cell carcinomac.961G>Ap.V321M20
48COSM144245PTCH1skin,NS,carcinoma,basal cell carcinomac.1585A>Tp.K529*20
49COSM11152TP53skin,NS,carcinoma,basal cell carcinomac.700T>Cp.Y234H20
50COSM17548PTCH1skin,NS,carcinoma,basal cell carcinomac.3499G>Tp.G1167W20

Copy number variations for Basal Cell Carcinoma from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
125690899820526498279247MutationPTCHBasal cell carcinoma

Expression for genes affiliated with Basal Cell Carcinoma

About this section
Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for genes affiliated with Basal Cell Carcinoma

About this section

Pathways related to Basal Cell Carcinoma according to KEGG:

34
id Name KEGG Source Accession
1Basal cell carcinomahsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathwaysScoreTop Affiliating Genes
110.1PTCH1, SHH
210.0GLI3, SHH
39.9GLI1, GLI2, SHH
4
Show member pathways
9.6GLI1, GLI3, HHIP, PTCH1
59.6GLI1, GLI2, PTCH1, SHH, SMO
6
Show member pathways
9.5PTCH1, PTCH2, SHH, SMO, WNT16
79.4CTNNB1, MMP11, TP53, WNT16
8
Show member pathways
9.3GLI2, HHIP, PTCH1, PTCH2, SHH, SMO
99.2CTNNB1, PTCH1, SHH, SMO, TP53, WNT16
109.1CTNNB1, GLI1, GLI2, PTCH1, PTCH2, SHH
11
Show member pathways
8.9KRT15, KRT17, KRT19, KRT20, KRT7
12
Show member pathways
8.8GLI1, GLI2, GLI3, PTCH1, PTCH2, SMO
13
Show member pathways
8.8GLI1, GLI2, GLI3, HHIP, PTCH1, SHH
14
Show member pathways
8.6GLI1, GLI2, GLI3, HHIP, PTCH1, PTCH2
157.9CTNNB1, GLI1, GLI2, GLI3, HHIP, PTCH1
16
Show member pathways
7.6CTNNB1, GLI1, GLI2, GLI3, HHIP, MC1R
17
Show member pathways
7.6CTNNB1, GLI1, GLI2, GLI3, HHIP, MC1R

GO Terms for genes affiliated with Basal Cell Carcinoma

About this section

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary membraneGO:006017010.6HHIP, PTCH1, SMO
2axonemeGO:000593010.6GLI1, GLI2, GLI3
3ciliary baseGO:009754610.4GLI1, GLI2, GLI3, SUFU
4cell peripheryGO:007194410.4CTNNB1, KRT17, KRT19
5ciliary tipGO:009754210.2GLI1, GLI2, GLI3, SMO, SUFU
6ciliumGO:000592910.1GLI1, GLI2, GLI3, PTCH1, SMO, SUFU
7intermediate filamentGO:00058828.9KRT15, KRT17, KRT19, KRT20, KRT7
8cytosolGO:00058297.6CTNNB1, GLI1, GLI2, GLI3, GSTM3, KRT15

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 96)
idNameGO IDScoreTop Affiliating Genes
1epidermal cell fate specificationGO:000995711.0PTCH1, PTCH2
2cellular response to cholesterolGO:007139711.0PTCH1, SMO
3mammary gland epithelial cell differentiationGO:006064410.9PTCH1, SMO
4mammary gland duct morphogenesisGO:006060310.9GLI2, PTCH1
5determination of left/right asymmetry in lateral mesodermGO:000314010.9SHH, SMO
6epithelial-mesenchymal cell signalingGO:006068410.9SHH, SMO
7positive regulation of epidermal cell differentiationGO:004560610.9PTCH1, PTCH2
8digestive tract morphogenesisGO:004854610.9GLI1, SHH
9notochord regressionGO:006003210.9GLI1, GLI2
10ectoderm developmentGO:000739810.9CTNNB1, SHH
11embryonic foregut morphogenesisGO:004861710.9CTNNB1, SHH
12cell differentiation involved in kidney developmentGO:006100510.9GLI3, PTCH1
13lung-associated mesenchyme developmentGO:006048410.9CTNNB1, SHH
14mesenchymal cell proliferation involved in lung developmentGO:006091610.9CTNNB1, SHH
15positive regulation of hh target transcription factor activityGO:000722810.9SHH, SMO
16positive regulation of T cell differentiation in thymusGO:003308910.8GLI2, SHH
17artery developmentGO:006084010.8GLI3, SHH
18positive regulation of epithelial cell proliferation involved in prostate gland developmentGO:006076910.8CTNNB1, SHH
19positive regulation of skeletal muscle tissue developmentGO:004864310.8CTNNB1, SHH
20negative regulation of alpha-beta T cell differentiationGO:004663910.8GLI3, SHH
21keratinocyte proliferationGO:004361610.8PTCH1, WNT16
22layer formation in cerebral cortexGO:002181910.8CTNNB1, GLI3
23negative thymic T cell selectionGO:004506010.8GLI3, SHH
24positive regulation of alpha-beta T cell differentiationGO:004663810.8GLI3, SHH
25cerebellar cortex morphogenesisGO:002169610.7GLI1, GLI2, SMO
26cell fate determinationGO:000170910.7CTNNB1, PTCH1, PTCH2
27oxidative stress-induced premature senescenceGO:009040310.7TP53, WNT16
28regulation of osteoblast differentiationGO:004566710.7CTNNB1, GLI1
29determination of left/right symmetryGO:000736810.7SHH, SMO, SUFU
30heart loopingGO:000194710.7SHH, SMO, SUFU
31cell fate specificationGO:000170810.7CTNNB1, SHH, SMO
32canonical Wnt signaling pathwayGO:006007010.7CTNNB1, GLI1, SHH
33positive regulation of smoothened signaling pathwayGO:004588010.7GLI1, SHH, SMO
34hindbrain developmentGO:003090210.7CTNNB1, GLI2, SHH
35embryonic limb morphogenesisGO:003032610.7GLI3, PTCH1, SHH
36mammary gland developmentGO:003087910.7GLI2, GLI3, PTCH1
37positive regulation of mesenchymal cell proliferationGO:000205310.6CTNNB1, SHH, SMO
38anatomical structure developmentGO:004885610.6GLI2, GLI3, SHH
39anatomical structure formation involved in morphogenesisGO:004864610.6GLI2, GLI3, SHH
40branching morphogenesis of an epithelial tubeGO:004875410.6GLI2, GLI3, SHH
41hindgut morphogenesisGO:000744210.6GLI2, GLI3, SHH
42forebrain developmentGO:003090010.6CTNNB1, GLI3, SHH
43replicative senescenceGO:009039910.6TP53, WNT16
44limb developmentGO:006017310.6CTNNB1, GLI3, SHH
45thalamus developmentGO:002179410.6SHH, SMO
46positive regulation of protein import into nucleusGO:004230710.6GLI3, SHH, SMO
47regulation of smoothened signaling pathwayGO:000858910.6GLI1, GLI2, PTCH1
48negative regulation of cell differentiationGO:004559610.6CTNNB1, GLI3, SHH
49intermediate filament organizationGO:004510910.6KRT17, KRT20, SHH
50epithelial tube branching involved in lung morphogenesisGO:006044110.6CTNNB1, HHIP, SHH

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1hedgehog receptor activityGO:000815811.0PTCH1, PTCH2
2smoothened bindingGO:000511910.8PTCH1, PTCH2
3patched bindingGO:000511310.8PTCH1, SHH, SMO
4hedgehog family protein bindingGO:009710810.7HHIP, PTCH1, PTCH2
5chromatin bindingGO:000368210.2CTNNB1, GLI1, GLI2, GLI3, TP53
6structural constituent of cytoskeletonGO:00052009.9KRT15, KRT17, KRT19, KRT20
7transcription regulatory region DNA bindingGO:00442129.7CTNNB1, GLI1, GLI2, TP53
8protein bindingGO:00055156.8CTNNB1, GLI1, GLI2, GLI3, GSTM3, HHIP

Sources for Basal Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet